Mien-Chie Hung – författare

The field of non-viral vector research has rapidly progressed since the publication of the first edition. This new edition is expanded to two separate volumes that contain in-depth discussions of different non-viral approaches, including cationic liposomes and polymers, naked DNA and various physical methods of delivery, as well as a comprehensive coverage of the molecular biological designs of the plasmid DNA for reduced toxicity, prolonged expression and tissue or disease specific genes. New developments such as the toxicity of the non-viral vectors and recent advances in nucleic acid therapeutics are fully covered in these volumes.

In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem Breast Cancer Chemosensitivity moves on to focus on the latest findings of molecular mechanisms of drug resistance. These include in-depth discussions on multidrug resistance by P-glycoprotein and the multidrug resistance protein family, resistance to therapeutic agent-induced apoptosis, cell cycle deregulation, deregulation of DNA repair, loss of tumor suppressor genes, integrin-mediated adhesion, insulin-like growth factors, epidermal growth factor, and ErbB2 in modulating breast cancer response to systemic therapy, especially, certain chemotherapeutic agents. Breast Cancer Chemosensitivity provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment.

Provides expert, state-of-the-art insight into the current progress of viral and non-viral gene therapy Translational medicine has opened the gateway to the era of personalized or precision medicine. No longer a one-size-fits-all approach, the treatment of cancer is now based on an understanding of underlying biologic mechanisms and is increasingly being tailored to the molecular specificity of a tumor.This book provides a comprehensive overview of the pertinent molecular discoveries in the cancer field and explains how these are being used for gene-based cancer therapies. Designed as a volume in the Translational Oncology book series, Cancer Gene Therapy by Viral and Non-viral Vectors deals with the practice of gene-therapy, with reference to vectors for gene expression and gene transfer, as well as viral therapy. It covers the history and current and future applications of gene transfer in cancer, and provides expert insight on the progress of viral and non-viral gene therapy with regard to delivery system, vector design, potential therapeutic genes, and principles and regulations for cancer gene therapy.Presented in three parts, Cancer Gene Therapy by Viral and Non-viral Vectors covers: Delivery Systems • Translational Cancer Research: Gene Therapy by Viral and Non-viral Vectors • Retroviruses for Cancer Therapy • DNA Plasmids for Non-viral Gene Therapy of Cancer • Cancer Therapy with RNAi delivered by Non-viral Membrane/Core Nanoparticles Targeted Expression • Cancer Gene Therapy by Tissue-specific and Cancer-targeting Promptors • MicroRNAs as Drugs and Drug Targets in CancerPrinciples of Clinical Trials in Gene Therapy • Regulatory issues for Manufacturers of Viral Vectors and Vector-transduced Cells for Phase I/II Trials • US Regulations Governing Clinical Trials in Gene Therapy • Remaining Obstacles to the Success of Cancer Gene TherapyFocusing on speeding the process in clinical cancer care by bringing therapies as quickly as possible from bench to bedside, Cancer Gene Therapy by Viral and Non-viral Vectors is an absolutely vital book for physicians, clinicians, researchers, and students involved in this area of medicine.